Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | BCHE | P06276 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18387167 | 0.84 | ACHE (0.34) | RIPK1 | |
| SCHEMBL17552744 | 0.84 | RIPK1 (0.44) | RIPK1HSD11B1BACE1CES2BCHE | |
| SCHEMBL13654025 | 0.83 | RIPK1 (0.38) | RIPK1HSD11B1BACE1CES2BCHE | |
| SCHEMBL8672980 | 0.79 | RIPK1 (0.35) | RIPK1HSD11B1BACE1CES2BCHE | |
| SCHEMBL21560254 | 0.78 | RIPK1 (0.36) | RIPK1HSD11B1BACE1CES2BCHE | |
| SCHEMBL1836851 | 0.78 | CA2 (0.54) | CA2 | |
| SCHEMBL21972331 | 0.78 | RIPK1 (0.35) | RIPK1 | |
| SCHEMBL25093511 | 0.78 | SOS1 (0.33) | — | |
| SCHEMBL6763814 | 0.74 | CA2 (0.48) | RIPK1HSD11B1BACE1CES2BCHE | |
| SCHEMBL11212180 | 0.73 | CA2 (0.65) | CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11059817-B2 | Potent antiviral pyrazolopyridine compounds | MAVS, VRK1, VRK2 | RIPK1 49/4885HSD11B1 4552/4885BACE1 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.